Involvement of Non-coding RNAs in Chemo- and Radioresistance of Colorectal Cancer. (Q38826542)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27573902%20AND%20SRC:MED&resulttype=core&format=json

22 March 2020

review article

1 reference

title

Involvement of Non-coding RNAs in Chemo- and Radioresistance of Colorectal Cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27573902%20AND%20SRC:MED&resulttype=core&format=json

22 March 2020

1 reference

Daniele Fanale

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27573902%20AND%20SRC:MED&resulttype=core&format=json

22 March 2020

Antonio Russo

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27573902%20AND%20SRC:MED&resulttype=core&format=json

22 March 2020

language of work or name

English

0 references

publication date

1 January 2016

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27573902%20AND%20SRC:MED&resulttype=core&format=json

Advances in Experimental Medicine and Biology

22 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27573902%20AND%20SRC:MED&resulttype=core&format=json

22 March 2020

volume

937

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27573902%20AND%20SRC:MED&resulttype=core&format=json

22 March 2020

page(s)

207-228

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27573902%20AND%20SRC:MED&resulttype=core&format=json

22 March 2020

cites work

Cancer statistics, 2015

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42059-2_11

Global cancer statistics, 2012

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42059-2_11

Annual report to the nation on the status of cancer, 1975-2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42059-2_11

Response evaluation following neoadjuvant treatment of pancreatic cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42059-2_11

MicroRNAs in colorectal cancer stem cells: new regulators of cancer stemness?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42059-2_11

New findings on primary and acquired resistance to anti-EGFR therapy in metastatic colorectal cancer: do all roads lead to RAS?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42059-2_11

Personalizing colon cancer adjuvant therapy: selecting optimal treatments for individual patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42059-2_11

Chemoprevention, chemotherapy, and chemoresistance in colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42059-2_11

Radiation resistance: Cancer stem cells (CSCs) and their enigmatic pro-survival signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42059-2_11

Molecular mechanisms of acquired resistance to tyrosine kinase targeted therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42059-2_11

Mechanism-based cancer therapy: resistance to therapy, therapy for resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42059-2_11

Prognostic and predictive biomarkers for targeted therapy in NSCLC: for whom the bell tolls?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42059-2_11

Prognostic vs predictive molecular biomarkers in colorectal cancer: is KRAS and BRAF wild type status required for anti-EGFR therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42059-2_11

Impact of microRNAs in resistance to chemotherapy and novel targeted agents in non-small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42059-2_11

The cancer biomarker problem

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42059-2_11

Noncoding RNAs in cancer and cancer stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42059-2_11

Novel classes of non-coding RNAs and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42059-2_11

The emergence of lncRNAs in cancer biology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42059-2_11

Prognostic value of long non-coding RNA MALAT1 in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42059-2_11

Characterization of global microRNA expression reveals oncogenic potential of miR-145 in metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42059-2_11

Decreased expression of miR-133a correlates with poor prognosis in colorectal cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42059-2_11

The role of microRNAs in cancer: diagnostic and prognostic biomarkers and targets of therapies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42059-2_11

MicroRNA signatures: novel biomarker for colorectal cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42059-2_11

MicroRNAs: predictors and modifiers of chemo- and radiotherapy in different tumour types

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42059-2_11

MicroRNAs and Their Therapeutic Potential for Human Diseases: MicroRNAs, miR-143 and -145, Function as Anti-oncomirs and the Application of Chemically Modified miR-143 as an Anti-cancer Drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42059-2_11

MicroRNAs: master regulators of drug resistance, stemness, and metastasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42059-2_11

Role of microRNA in anticancer drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42059-2_11

MicroRNAs: short non-coding players in cancer chemoresistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42059-2_11

Emerging roles for modulation of microRNA signatures in cancer chemoprevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42059-2_11

Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42059-2_11

Adjuvant colon cancer chemotherapy: where we are and where we'll go.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42059-2_11

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42059-2_11

Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42059-2_11

Molecular mechanisms of drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42059-2_11

Harnessing the complexity of DNA-damage response pathways to improve cancer treatment outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42059-2_11

Epigenetics and chemoresistance in colorectal cancer: an opportunity for treatment tailoring and novel therapeutic strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42059-2_11

Thymidylate synthase expression and prognosis in colorectal cancer: a meta-analysis of colorectal cancer survival data.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42059-2_11

Amplification of thymidylate synthetase in metastatic colorectal cancer patients pretreated with 5-fluorouracil-based chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42059-2_11

Analysis of the thymidylate synthase gene structure in colorectal cancer patients and its possible relation with the 5-Fluorouracil drug response

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42059-2_11

Decreased levels of UMP kinase as a mechanism of fluoropyrimidine resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42059-2_11

Predictive and prognostic markers for the outcome of chemotherapy in advanced colorectal cancer, a retrospective analysis of the phase III randomised CAIRO study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42059-2_11

Irinotecan and its active metabolite, SN-38: review of bioanalytical methods and recent update from clinical pharmacology perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42059-2_11

Epigenetic biomarkers of colorectal cancer: Focus on DNA methylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42059-2_11

Epigenetic mechanisms of irinotecan sensitivity in colorectal cancer cell lines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42059-2_11

Cellular effects of CPT-11 on colon carcinoma cells: dependence on p53 and hMLH1 status

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42059-2_11

DNA strand breaks and apoptosis induced by oxaliplatin in cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42059-2_11

Recognition and processing of cisplatin- and oxaliplatin-DNA adducts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42059-2_11

Epigenetic Alterations in Colorectal Cancer: Emerging Biomarkers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42059-2_11

MicroRNA-10b is a prognostic indicator in colorectal cancer and confers resistance to the chemotherapeutic agent 5-fluorouracil in colorectal cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42059-2_11

Role of miR-19b and its target mRNAs in 5-fluorouracil resistance in colon cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42059-2_11

The splicing-factor related protein SFPQ/PSF interacts with RAD51D and is necessary for homology-directed repair and sister chromatid cohesion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42059-2_11

Involvement of Matrin 3 and SFPQ/NONO in the DNA damage response

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42059-2_11

Cell cycle regulation by the B-Myb transcription factor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42059-2_11

miR-20a targets BNIP2 and contributes chemotherapeutic resistance in colorectal adenocarcinoma SW480 and SW620 cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42059-2_11

Cleavage of BNIP-2 and BNIP-XL by caspases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42059-2_11

Clinical correlations of miR-21 expression in colorectal cancer patients and effects of its inhibition on DLD1 colon cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42059-2_11

MicroRNA-21 induces resistance to 5-fluorouracil by down-regulating human DNA MutS homolog 2 (hMSH2)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42059-2_11

Targeting miR-21 enhances the sensitivity of human colon cancer HT-29 cells to chemoradiotherapy in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42059-2_11

Down-regulation of miR-21 Induces Differentiation of Chemoresistant Colon Cancer Cells and Enhances Susceptibility to Therapeutic Regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42059-2_11

Inhibition of autophagy augments 5-fluorouracil chemotherapy in human colon cancer in vitro and in vivo model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42059-2_11

MicroRNA-23a antisense enhances 5-fluorouracil chemosensitivity through APAF-1/caspase-9 apoptotic pathway in colorectal cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42059-2_11

Suppression of microRNA-31 increases sensitivity to 5-FU at an early stage, and affects cell migration and invasion in HCT-116 colon cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42059-2_11

Dysregulation of microRNA-34a expression causes drug-resistance to 5-FU in human colon cancer DLD-1 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42059-2_11

Repression of c-Kit by p53 is mediated by miR-34 and is associated with reduced chemoresistance, migration and stemness

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42059-2_11

Extracellular disposal of tumor-suppressor miRs-145 and -34a via microvesicles and 5-FU resistance of human colon cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42059-2_11

Putative tumor suppressor miR‐145 inhibits colon cancer cell growth by targeting oncogene friend leukemia virus integration 1 gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42059-2_11

Tumor suppressor miR-145 reverses drug resistance by directly targeting DNA damage-related gene RAD18 in colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42059-2_11

SNAI2 modulates colorectal cancer 5-fluorouracil sensitivity through miR145 repression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42059-2_11

Overexpression of microRNA-122 re-sensitizes 5-FU-resistant colon cancer cells to 5-FU through the inhibition of PKM2 in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42059-2_11

miR-129 promotes apoptosis and enhances chemosensitivity to 5-fluorouracil in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42059-2_11

Mechanism of chemoresistance mediated by miR-140 in human osteosarcoma and colon cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42059-2_11

HDAC4 promotes growth of colon cancer cells via repression of p21.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42059-2_11

MicroRNA-143 reduces viability and increases sensitivity to 5-fluorouracil in HCT116 human colorectal cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42059-2_11

MicroRNA-143 inhibits tumor growth and angiogenesis and sensitizes chemosensitivity to oxaliplatin in colorectal cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42059-2_11

The clinical significance of MiR-148a as a predictive biomarker in patients with advanced colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42059-2_11

miR-192/miR-215 influence 5-fluorouracil resistance through cell cycle-mediated mechanisms complementary to its post-transcriptional thymidilate synthase regulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42059-2_11

miR-192 Regulates dihydrofolate reductase and cellular proliferation through the p53-microRNA circuit

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42059-2_11

Prognostic and predictive value of a microRNA signature in stage II colon cancer: a microRNA expression analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42059-2_11

Molecular mechanism of chemoresistance by miR-215 in osteosarcoma and colon cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42059-2_11

Role of miR-200 family members in survival of colorectal cancer patients treated with fluoropyrimidines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42059-2_11

Curcumin mediates chemosensitization to 5-fluorouracil through miRNA-induced suppression of epithelial-to-mesenchymal transition in chemoresistant colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42059-2_11

miR-203 enhances chemosensitivity to 5-fluorouracil by targeting thymidylate synthase in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42059-2_11

miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42059-2_11

MicroRNA-224 is associated with colorectal cancer progression and response to 5-fluorouracil-based chemotherapy by KRAS-dependent and -independent mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42059-2_11

MicroRNA-497 targets insulin-like growth factor 1 receptor and has a tumour suppressive role in human colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42059-2_11

Exploiting a novel miR-519c-HuR-ABCG2 regulatory pathway to overcome chemoresistance in colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42059-2_11

MicroRNA-520g confers drug resistance by regulating p21 expression in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42059-2_11

MicroRNA-451 is involved in the self-renewal, tumorigenicity, and chemoresistance of colorectal cancer stem cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42059-2_11

Tumor suppressor functions of miR-133a in colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42059-2_11

miR-153 supports colorectal cancer progression via pleiotropic effects that enhance invasion and chemotherapeutic resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42059-2_11

FOXO3a mediates the cytotoxic effects of cisplatin in colon cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42059-2_11

High miR-196a levels promote the oncogenic phenotype of colorectal cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42059-2_11

Induction of epithelial-mesenchymal transition and down-regulation of miR-200c and miR-141 in oxaliplatin-resistant colorectal cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42059-2_11

MiR-222 modulates multidrug resistance in human colorectal carcinoma by down-regulating ADAM-17.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42059-2_11

miR-297 modulates multidrug resistance in human colorectal carcinoma by down-regulating MRP-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42059-2_11

miR-1915 inhibits Bcl-2 to modulate multidrug resistance by increasing drug-sensitivity in human colorectal carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42059-2_11

High expression of microRNA-625-3p is associated with poor response to first-line oxaliplatin based treatment of metastatic colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42059-2_11

A long non-coding RNA snaR contributes to 5-fluorouracil resistance in human colon cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42059-2_11

Targeted therapy in metastatic colorectal cancer -- an example of personalised medicine in action.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42059-2_11

Future of targeted agents in metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42059-2_11

Targeting angiogenesis: progress with anti-VEGF treatment with large molecules

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42059-2_11

How to find the Ariadne's thread in the labyrinth of salvage treatment options for metastatic colorectal cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42059-2_11

Antiangiogenesis therapy in the treatment of metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42059-2_11

Vascular endothelial growth factor D expression is a potential biomarker of bevacizumab benefit in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42059-2_11

The association of alternate VEGF ligands with resistance to anti-VEGF therapy in metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42059-2_11

Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42059-2_11

Pharmacogenomics of intrinsic and acquired pharmacoresistance in colorectal cancer: Toward targeted personalized therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42059-2_11

MicroRNAs as novel predictive biomarkers and therapeutic targets in colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42059-2_11

MicroRNAs targeting EGFR signalling pathway in colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42059-2_11

Specific alterations of microRNA transcriptome and global network structure in colorectal carcinoma after cetuximab treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42059-2_11

High let-7a microRNA levels in KRAS-mutated colorectal carcinomas may rescue anti-EGFR therapy effects in patients with chemotherapy-refractory metastatic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42059-2_11

MicroRNA signature in metastatic colorectal cancer patients treated with anti-EGFR monoclonal antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42059-2_11

Identification of a microRNA expression signature for chemoradiosensitivity of colorectal cancer cells, involving miRNAs-320a, -224, -132 and let7g.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42059-2_11

A let-7 microRNA-binding site polymorphism in KRAS predicts improved outcome in patients with metastatic colorectal cancer treated with salvage cetuximab/panitumumab monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42059-2_11

A let-7 microRNA-binding site polymorphism in 3'-untranslated region of KRAS gene predicts response in wild-type KRAS patients with metastatic colorectal cancer treated with cetuximab monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42059-2_11

A let-7 microRNA SNP in the KRAS 3'UTR is prognostic in early-stage colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42059-2_11

MicroRNA-7 expression in colorectal cancer is associated with poor prognosis and regulates cetuximab sensitivity via EGFR regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42059-2_11

MiR-199a-5p and miR-375 affect colon cancer cell sensitivity to cetuximab by targeting PHLPP1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42059-2_11

The predictive value of microRNA-126 in relation to first line treatment with capecitabine and oxaliplatin in patients with metastatic colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42059-2_11

MicroRNA-126 and epidermal growth factor-like domain 7-an angiogenic couple of importance in metastatic colorectal cancer. Results from the Nordic ACT trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42059-2_11

Changes in circulating microRNA-126 during treatment with chemotherapy and bevacizumab predicts treatment response in patients with metastatic colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42059-2_11

Epigenetics meets radiation biology as a new approach in cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42059-2_11

Defining the tumour and target volumes for radiotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42059-2_11

The concurrent chemoradiation paradigm--general principles

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42059-2_11

Strategies to improve radiotherapy with targeted drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42059-2_11

Randomized phase III study comparing preoperative radiotherapy with chemoradiotherapy in nonresectable rectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42059-2_11

Oncologic impact of pathologic response on clinical outcome after preoperative chemoradiotherapy in locally advanced rectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42059-2_11

Cancer stem cells in solid tumours: accumulating evidence and unresolved questions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42059-2_11

DNA repair in murine embryonic stem cells and differentiated cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42059-2_11

Coordination of DNA mismatch repair and base excision repair processing of chemotherapy and radiation damage for targeting resistant cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42059-2_11

p53: traffic cop at the crossroads of DNA repair and recombination

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42059-2_11

DNA base repair--recognition and initiation of catalysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42059-2_11

Association of breast cancer stem cells identified by aldehyde dehydrogenase 1 expression with resistance to sequential Paclitaxel and epirubicin-based chemotherapy for breast cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42059-2_11

Role of cell cycle in epidermal growth factor receptor inhibitor-mediated radiosensitization

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42059-2_11

A specific miRNA signature correlates with complete pathological response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42059-2_11

Radiation-induced microRNA-622 causes radioresistance in colorectal cancer cells by down-regulating Rb

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42059-2_11

Novel Epigenetic CREB-miR-630 Signaling Axis Regulates Radiosensitivity in Colorectal Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42059-2_11

MiR-106b induces cell radioresistance via the PTEN/PI3K/AKT pathways and p21 in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42059-2_11

Role of primary miRNA polymorphic variants in metastatic colon cancer patients treated with 5-fluorouracil and irinotecan

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42059-2_11

Genomics and cancer drug resistance.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42059-2_11

Platinum resistance: the role of DNA repair pathways

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42059-2_11

Modification of miR gene expression pattern in human colon cancer cells following exposure to 5-fluorouracil in vitro

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42059-2_11

MiR-22 regulates 5-FU sensitivity by inhibiting autophagy and promoting apoptosis in colorectal cancer cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42059-2_11

Inhibition of lactate dehydrogenase A by microRNA-34a resensitizes colon cancer cells to 5-fluorouracil

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42059-2_11

MicroRNA expression profiling identifies miR-31-5p/3p as associated with time to progression in wild-type RAS metastatic colorectal cancer treated with cetuximab.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42059-2_11

LincRNA-p21 enhances the sensitivity of radiotherapy for human colorectal cancer by targeting the Wnt/β-catenin signaling pathway

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-42059-2_11

10.1007/978-3-319-42059-2_11

31 March 2020

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27573902%20AND%20SRC:MED&resulttype=core&format=json

22 March 2020

1 reference